Prophylactic effect of N-acetyl-cysteine plus Atorvastatin versus N-acetyl-cysteine and Atorvastatin alone for the prevention of contrast induced nephropathy in patients undergoing elective angiography with or without percutaneous coronary intervention: a single center prospective randomized controlled trial
Red color represents old content. It may be empty showing addition in the new version.
Green color represents new content. It may be empty showing deletion in the new version.
Inline
Side by side
Added new contents,
deleted old contents,contents that are not changed.
New table contents
New table contents
Old table contents
Old table contents
Unchanged contents
Unchanged contents
Added new contents, contents that are not changed.
Deleted old contents, contents that are not changed.
Old table contents
Old table contents
Unchanged contents
Unchanged contents
New table contents
New table contents
Unchanged contents
Unchanged contents
Protocol summary
This investigation included 120 participants admitting for elective coronary angiography with or without percutaneous coronary intervention in Ali-ebn Abitaleb Hospital, Shiraz, Iran. After being qualified for study entrance, the patients were obtained an informed consent and were randomly categorized in 4 groups. This study is also single blind, so patients do not notified whether they were in intervention or control group.
This investigation included 250 participants admitting for elective coronary angiography with or without percutaneous coronary intervention in Ali-ebn Abitaleb Hospital, Shiraz, Iran. After being qualified for study entrance, the patients were obtained an informed consent and were randomly categorized in 4 groups. This study is also single blind, so patients do not notified whether they were in intervention or control group.
This investigation included 120250 participants admitting for elective coronary angiography with or without percutaneous coronary intervention in Ali-ebn Abitaleb Hospital, Shiraz, Iran. After being qualified for study entrance, the patients were obtained an informed consent and were randomly categorized in 4 groups. This study is also single blind, so patients do not notified whether they were in intervention or control group.
این مطالعه 120 بیمار را که در بیمارستان علی ابن ابیطالب جهت انجام آنژیوگرافی با و بدون مداخله پوستی کرونر پذیرش شده اند را در بر می گیرد.در این مطالعه پس از احراز شرایط ورود به مطالعه و توضیح در رابطه بااین مطالعه و اخذ رضایت افراد واجد شرایط به چهار گروه تقسیم بندی می شوند. همچنین این مطالعه به صورت یک سو کور می باشدبه طوری که بیماران از قرار گیری در گروه کنترل یا مداخله اطلاعی ندارند
این مطالعه 250 بیمار را که در بیمارستان علی ابن ابیطالب جهت انجام آنژیوگرافی با و بدون مداخله پوستی کرونر پذیرش شده اند را در بر می گیرد.در این مطالعه پس از احراز شرایط ورود به مطالعه و توضیح در رابطه بااین مطالعه و اخذ رضایت افراد واجد شرایط به چهار گروه تقسیم بندی می شوند. همچنین این مطالعه به صورت یک سو کور می باشدبه طوری که بیماران از قرار گیری در گروه کنترل یا مداخله اطلاعی ندارند
این مطالعه 120250 بیمار را که در بیمارستان علی ابن ابیطالب جهت انجام آنژیوگرافی با و بدون مداخله پوستی کرونر پذیرش شده اند را در بر می گیرد.در این مطالعه پس از احراز شرایط ورود به مطالعه و توضیح در رابطه بااین مطالعه و اخذ رضایت افراد واجد شرایط به چهار گروه تقسیم بندی می شوند. همچنین این مطالعه به صورت یک سو کور می باشدبه طوری که بیماران از قرار گیری در گروه کنترل یا مداخله اطلاعی ندارند
Eligible patients consist of individuals older than 21 years old with normal and abnormal renal function (creatinine clearance between 15 and 60 mL/min or serum creatinine (SCr) ≥1.1 mg/dL) undergoing elective cardiac catheterization with or without PCI.
Exclusion criteria: patients with end-stage renal failure (glomerular filtration rate (GFR) ≤ 15 mL/min); history of previous dialysis; pulmonary edema; emergency cardiac catheterization (patients with ST-segment elevation myocardial infarction undergoing primary PCI ); exposure to contrast within previous two days ago before procedure; allergies to contrast media; liver disease and contraindication to statins.
Eligible patients consist of individuals older than 21 years old with abnormal renal function (creatinine clearance between 15 and 60 mL/min or serum creatinine (SCr) ≥1.1 mg/dL) undergoing elective cardiac catheterization with or without PCI.
Exclusion criteria: patients with end-stage renal failure (glomerular filtration rate (GFR) ≤ 15 mL/min); history of previous dialysis; pulmonary edema; emergency cardiac catheterization (patients with ST-segment elevation myocardial infarction undergoing primary PCI ); exposure to contrast within previous two days ago before procedure; allergies to contrast media; liver disease and contraindication to statins.
Eligible patients consist of individuals older than 21 years old with normal and abnormal renal function (creatinine clearance between 15 and 60 mL/min or serum creatinine (SCr) ≥1.1 mg/dL) undergoing elective cardiac catheterization with or without PCI. Exclusion criteria: patients with end-stage renal failure (glomerular filtration rate (GFR) ≤ 15 mL/min); history of previous dialysis; pulmonary edema; emergency cardiac catheterization (patients with ST-segment elevation myocardial infarction undergoing primary PCI ); exposure to contrast within previous two days ago before procedure; allergies to contrast media; liver disease and contraindication to statins.
افراد واجد شرایط شامل بیماران با سن بیشتر از 21 سال با عملکرد کلیه طبیعی و غیر طبیعی در محدوده کلیرانس کراتینین 15 الی 60 mL/min یا سرم کراتینین بیشتر از 1.1 mg/dL که به صورت الکتیو تحت کاتتریزاسیون قلبی با یا بدون انجام PCI قرار می گیرند
معیارهای خروج از مطالعه شامل افراد End-stage renal failure با فیلتراسیون گلومرولی(GFR) کمتر از 15 ، سابقه دیالیز قبلی ، ادم ریه ،کاتتریزاسیون اورژانسی قلبی( بیمار ان با انفارکتوس قلبی همراه صعود قطعه ST که تحت PCI اولیه قرار می گیرند) ، می باشند .سایر معیارهای خروج از مطالعه شامل قرار گرفتن در معرض کنتراست در دو روز گذشته؛ آلرژی به کنتراست ،کنتراندیکاسیون استاتین ها واختلال کبدی می باشد
افراد واجد شرایط شامل بیماران با سن بیشتر از 21 سال با عملکرد کلیه غیر طبیعی در محدوده کلیرانس کراتینین 15 الی 60 mL/min یا سرم کراتینین بیشتر از 1.1 mg/dL که به صورت الکتیو تحت کاتتریزاسیون قلبی با یا بدون انجام PCI قرار می گیرند
معیارهای خروج از مطالعه شامل افراد End-stage renal failure با فیلتراسیون گلومرولی(GFR) کمتر از 15 ، سابقه دیالیز قبلی ، ادم ریه ،کاتتریزاسیون اورژانسی قلبی( بیمار ان با انفارکتوس قلبی همراه صعود قطعه ST که تحت PCI اولیه قرار می گیرند) ، می باشند .سایر معیارهای خروج از مطالعه شامل قرار گرفتن در معرض کنتراست در دو روز گذشته؛ آلرژی به کنتراست ،کنتراندیکاسیون استاتین ها واختلال کبدی می باشد
افراد واجد شرایط شامل بیماران با سن بیشتر از 21 سال با عملکرد کلیه طبیعی و غیر طبیعی در محدوده کلیرانس کراتینین 15 الی 60 mL/min یا سرم کراتینین بیشتر از 1.1 mg/dL که به صورت الکتیو تحت کاتتریزاسیون قلبی با یا بدون انجام PCI قرار می گیرند معیارهای خروج از مطالعه شامل افراد End-stage renal failure با فیلتراسیون گلومرولی(GFR) کمتر از 15 ، سابقه دیالیز قبلی ، ادم ریه ،کاتتریزاسیون اورژانسی قلبی( بیمار ان با انفارکتوس قلبی همراه صعود قطعه ST که تحت PCI اولیه قرار می گیرند) ، می باشند .سایر معیارهای خروج از مطالعه شامل قرار گرفتن در معرض کنتراست در دو روز گذشته؛ آلرژی به کنتراست ،کنتراندیکاسیون استاتین ها واختلال کبدی می باشد
General information
120
250
120250
120
empty
120
empty
The inclusion criteria were mistakenly written for people with normal kidney function, which has now been corrected
The inclusion criteria were mistakenly written for people with normal kidney function, which has now been corrected
empty
در مورد شرایط ورود به مطالعه به اشتباه افراد با عملکرد طبیعی کلیه نوشته شده بود که هم اکنون اصلاح گردید
در مورد شرایط ورود به مطالعه به اشتباه افراد با عملکرد طبیعی کلیه نوشته شده بود که هم اکنون اصلاح گردید
Eligible patients include individuals older than 21 years old
Normal and abnormal renal function (Creatinine clearance between 15 and 60 mL/min or serum creatinine (SCr) ≥1.1 mg/dL)
Undergoing elective cardiac catheterization with or without PCI
Eligible patients include individuals older than 21 years old
abnormal renal function (Creatinine clearance between 15 and 60 mL/min or serum creatinine (SCr) ≥1.1 mg/dL)
Undergoing elective cardiac catheterization with or without PCI
Eligible patients include individuals older than 21 years old Normal and abnormal renal function (Creatinine clearance between 15 and 60 mL/min or serum creatinine (SCr) ≥1.1 mg/dL) Undergoing elective cardiac catheterization with or without PCI
افراد واجد شرایط شامل بیماران با سن بیشتر از 21 سال
با عملکرد کلیه طبیعی و غیر طبیعی در محدوده کلیرانس کراتینین 15 الی 60 mL/min یا سرم کراتینین بیشتر از 1.1 mg/dL
که به صورت الکتیو تحت کاتتریزاسیون قلبی با یا بدون انجام PCI قرار می گیرند
افراد واجد شرایط شامل بیماران با سن بیشتر از 21 سال
با عملکرد کلیه غیر طبیعی در محدوده کلیرانس کراتینین 15 الی 60 mL/min یا سرم کراتینین بیشتر از 1.1 mg/dL
که به صورت الکتیو تحت کاتتریزاسیون قلبی با یا بدون انجام PCI قرار می گیرند
افراد واجد شرایط شامل بیماران با سن بیشتر از 21 سال با عملکرد کلیه طبیعی و غیر طبیعی در محدوده کلیرانس کراتینین 15 الی 60 mL/min یا سرم کراتینین بیشتر از 1.1 mg/dL که به صورت الکتیو تحت کاتتریزاسیون قلبی با یا بدون انجام PCI قرار می گیرند
Intervention groups
#1
Intervention group: Group II was received Atorvastatin 40 mg before and after coronary procedures (Atorvastatin 80 mg).
Intervention group: Group II was received Atorvastatin 80mg before coronary procedures (Atorvastatin 80 mg).
Intervention group: Group II was received Atorvastatin 40 mg80mg before and after coronary procedures (Atorvastatin 80 mg).
گروه مداخله: گروه دوم قبل و بعد از پروسیجر کرونری40 میلی گرم اتوروستاتین دریافت می کنند (Atorvastatin 80 mg group)
گروه مداخله: گروه دوم قبل و بعد از پروسیجر کرونری80 میلی گرم اتوروستاتین دریافت می کنند (Atorvastatin 80 mg group)
گروه مداخله: گروه دوم قبل و بعد از پروسیجر کرونری40کرونری80 میلی گرم اتوروستاتین دریافت می کنند (Atorvastatin 80 mg group)
#2
Intervention group: Group IV was prescribed 40 mg of Atorvastatin before and after the coronary procedure plus N-acetylcysteine as a sum of 1200 mg before and 600 mg after the coronary procedure (Atorvastatin 80 mg plus NAC 1800 mg).
Intervention group: Group IV was prescribed 80 mg of Atorvastatin before and after the coronary procedure plus N-acetylcysteine as a sum of 1200 mg before and 600 mg after the coronary procedure (Atorvastatin 80 mg plus NAC 1800 mg).
Intervention group: Group IV was prescribed 4080 mg of Atorvastatin before and after the coronary procedure plus N-acetylcysteine as a sum of 1200 mg before and 600 mg after the coronary procedure (Atorvastatin 80 mg plus NAC 1800 mg).
گروه مداخله: گروه چهارم قبل و بعد از پروسیجر کرونری40 میلی گرم اتوروستاتین و ان استیل سیستئین با دوز 600 میلی گرم خوراکی به صورت بولوس 12 ساعت قبل از پروسیجر و اندکی قبل از پروسیجر و اندکی بعد از پروسیجر کرونری مجموعا 1200 میلی گرم قبل از پروسیجر و600 میلی گرم بعد از پروسیجر دریافت می کنند (NAC 1800 mg plus Atorvastatin 80 mg group )
گروه مداخله: گروه چهارم قبل و بعد از پروسیجر کرونری80 میلی گرم اتوروستاتین و ان استیل سیستئین با دوز 600 میلی گرم خوراکی به صورت بولوس 12 ساعت قبل از پروسیجر و اندکی قبل از پروسیجر و اندکی بعد از پروسیجر کرونری مجموعا 1200 میلی گرم قبل از پروسیجر و600 میلی گرم بعد از پروسیجر دریافت می کنند (NAC 1800 mg plus Atorvastatin 80 mg group )
گروه مداخله: گروه چهارم قبل و بعد از پروسیجر کرونری40کرونری80 میلی گرم اتوروستاتین و ان استیل سیستئین با دوز 600 میلی گرم خوراکی به صورت بولوس 12 ساعت قبل از پروسیجر و اندکی قبل از پروسیجر و اندکی بعد از پروسیجر کرونری مجموعا 1200 میلی گرم قبل از پروسیجر و600 میلی گرم بعد از پروسیجر دریافت می کنند (NAC 1800 mg plus Atorvastatin 80 mg group )
Recruitment centers
#1
Name of recruitment center - English: Ali-ebn abitaleb hospital
Name of recruitment center - Persian: بیمارستان علی ابن ابی طالب
Full name of responsible person - English: saeed keshtkar
Full name of responsible person - Persian: سعید کشتکار
Street address - English: First Floor, Karandish Martyr 14, Safar Street, Shiraz, Fars Province, Iran
Street address - Persian: شیراز خیابان سفر کوچه 14 کار اندیش
City - English: SHIRAZ
City - Persian: شیراز
Province: Fars
Country: Iran (Islamic Republic of)
Postal code: 7145734411
Phone: +98 71 3225 8032
Fax:
Email: s.keshtkar20@gmail.com
Web page address:
Name of recruitment center - English: Ali-ebn Abitaleb hospital
Name of recruitment center - Persian: بیمارستان علی ابن ابی طالب
Full name of responsible person - English: Saeed Keshtkar
Full name of responsible person - Persian: سعید کشتکار
Street address - English: Ali-ebn Abitaleb hospital, Salamat Blvd., Khalij Fars high way
Street address - Persian: بزرگراه خلیج فارس-بلوارسلامت-بیمارستان فوق تخصصی علی ابن ابیطالب (ع)
City - English: Zahedan
City - Persian: زاهدان
Province: Sistan-va-Balouchestan
Country: Iran (Islamic Republic of)
Postal code: 9816743111
Phone: +98 54 3329 5570
Fax:
Email: s.keshtkar20@gmail.com
Web page address:
Name of recruitment center - English: Ali-ebn abitalebAbitaleb hospital Name of recruitment center - Persian: بیمارستان علی ابن ابی طالب Full name of responsible person - English: saeed keshtkarSaeed Keshtkar Full name of responsible person - Persian: سعید کشتکار Street address - English: First FloorAli-ebn Abitaleb hospital, Karandish Martyr 14Salamat Blvd., Safar Street, Shiraz,Khalij Fars Province, Iranhigh way Street address - Persian: شیراز خیابان سفر کوچه 14 کار اندیشبزرگراه خلیج فارس-بلوارسلامت-بیمارستان فوق تخصصی علی ابن ابیطالب (ع) City - English: SHIRAZZahedan City - Persian: شیراززاهدان Province: FarsSistan-va-Balouchestan Country: Iran (Islamic Republic of) Postal code: 71457344119816743111 Phone: +98 71 3225 803254 3329 5570 Fax: Email: s.keshtkar20@gmail.com Web page address:
Sponsors / Funding sources
#1
Name of organization / entity - English:
Name of organization / entity - Persian:
Full name of responsible person - English: nour mohammad bakhshani
Full name of responsible person - Persian: نور محمد بخشانی
Street address - English: zahedan university of medical science ,dr hesabi square,zahedan
Street address - Persian: زاهدان ، میدان دکتر حسابی ،پردیس دانشگاه علوم پزشکی زاهدان
City - English: zahedan
City - Persian: زاهدان
Province: Sistan-va-Balouchestan
Country: Iran (Islamic Republic of)
Postal code: 9816737789
Phone: +98 54 3329 5717
Fax:
Email: parcomss97@gmail.com
Web page address:
Name of organization / entity - English:
Name of organization / entity - Persian:
Full name of responsible person - English: Nour Mohammad Bakhshani
Full name of responsible person - Persian: نور محمد بخشانی
Street address - English: Zahedan University of Medical Sciences, Dr Hesabi square
Street address - Persian: زاهدان ، میدان دکتر حسابی ،پردیس دانشگاه علوم پزشکی زاهدان
City - English: zahedan
City - Persian: زاهدان
Province: Sistan-va-Balouchestan
Country: Iran (Islamic Republic of)
Postal code: 9816737789
Phone: +98 54 3329 5717
Fax:
Email: parcomss97@gmail.com
Web page address:
Name of organization / entity - English: Name of organization / entity - Persian: Full name of responsible person - English: nour mohammad bakhshaniNour Mohammad Bakhshani Full name of responsible person - Persian: نور محمد بخشانی Street address - English: zahedan universityZahedan University of medical science Medical Sciences,dr hesabi square,zahedan Dr Hesabi square Street address - Persian: زاهدان ، میدان دکتر حسابی ،پردیس دانشگاه علوم پزشکی زاهدان City - English: zahedan City - Persian: زاهدان Province: Sistan-va-Balouchestan Country: Iran (Islamic Republic of) Postal code: 9816737789 Phone: +98 54 3329 5717 Fax: Email: parcomss97@gmail.com Web page address:
Protocol summary
Study aim
Prophylactic role of NAC and Atorvastatin in preventing contrast induced nephropathy in patients undergoing angiography with or without PCI
Design
This single blind randomized controlled trial will be performed as a community-based and pragmatic control group with parallel groups.
Settings and conduct
This investigation included 250 participants admitting for elective coronary angiography with or without percutaneous coronary intervention in Ali-ebn Abitaleb Hospital, Shiraz, Iran. After being qualified for study entrance, the patients were obtained an informed consent and were randomly categorized in 4 groups. This study is also single blind, so patients do not notified whether they were in intervention or control group.
Participants/Inclusion and exclusion criteria
Eligible patients consist of individuals older than 21 years old with abnormal renal function (creatinine clearance between 15 and 60 mL/min or serum creatinine (SCr) ≥1.1 mg/dL) undergoing elective cardiac catheterization with or without PCI.
Exclusion criteria: patients with end-stage renal failure (glomerular filtration rate (GFR) ≤ 15 mL/min); history of previous dialysis; pulmonary edema; emergency cardiac catheterization (patients with ST-segment elevation myocardial infarction undergoing primary PCI ); exposure to contrast within previous two days ago before procedure; allergies to contrast media; liver disease and contraindication to statins.
Intervention groups
These individuals were randomly categorized in 4 groups with the following features: Group I (considered as control), Group II (statin 80 mg), Group III (NAC 1800 mg) and Group IV (statin 80 mg plus NAC 1800 mg)
Main outcome variables
The primary outcome was CIN and the secondary clinical end points were hemodialysis and mortality within 48 hours after contrast media exposure .
General information
Reason for update
The inclusion criteria were mistakenly written for people with normal kidney function, which has now been corrected
Acronym
IRCT registration information
IRCT registration number:IRCT20180417039347N1
Registration date:2018-11-20, 1397/08/29
Registration timing:prospective
Last update:2020-07-28, 1399/05/07
Update count:2
Registration date
2018-11-20, 1397/08/29
Registrant information
Name
Saeed KESHTKAR
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 71 3225 8032
Email address
s.keshtkar20@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2018-11-22, 1397/09/01
Expected recruitment end date
2018-12-21, 1397/09/30
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Prophylactic effect of N-acetyl-cysteine plus Atorvastatin versus N-acetyl-cysteine and Atorvastatin alone for the prevention of contrast induced nephropathy in patients undergoing elective angiography with or without percutaneous coronary intervention: a single center prospective randomized controlled trial
Public title
Prophylactic effect of N-acetyl-cysteine plus Atorvastatin versus N-acetyl-cysteine and Atorvastatin alone for the prevention of contrast induced nephropathy
Purpose
Prevention
Inclusion/Exclusion criteria
Inclusion criteria:
Eligible patients include individuals older than 21 years old
abnormal renal function (Creatinine clearance between 15 and 60 mL/min or serum creatinine (SCr) ≥1.1 mg/dL)
Undergoing elective cardiac catheterization with or without PCI
Exclusion criteria:
Patients with end-stage renal failure (glomerular filtration rate (GFR) ≤ 15 mL/min),
history of previous dialysis
pulmonary edema
emergency cardiac catheterization (patients with ST-segment elevation myocardial infarction undergoing primary PCI ),
exposure to contrast within previous two days ago before procedure
allergies to contrast media,
contraindication to statins
liver disease
Age
From 21 years old
Gender
Both
Phase
3
Groups that have been masked
Participant
Sample size
Target sample size:
250
Randomization (investigator's opinion)
Randomized
Randomization description
In this study, random allocation method using variable blocks was used by statistical software for experimental and control groups
Blinding (investigator's opinion)
Single blinded
Blinding description
In this study, patients have been blinded about the intervention protocols .
Placebo
Not used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics committee of zahedan university of medical science
Street address
Zahedan University of Medical Science, Dr Hesabi square, Zahedan
City
Zahedan
Province
Sistan-va-Balouchestan
Postal code
9816737789
Approval date
2018-09-23, 1397/07/01
Ethics committee reference number
IR.ZAUMS.REC.1397.254
Health conditions studied
1
Description of health condition studied
Contrast induced nephropathy
ICD-10 code
T80.8
ICD-10 code description
Other complications following infusion, transfusion and therapeutic injection
Primary outcomes
1
Description
Serum creatinine level
Timepoint
Serum creatinine levels are measured on the first day (day before the procedure) and 48 hours after exposure.
Method of measurement
creatinine test
Secondary outcomes
1
Description
Need for hemodialysis
Timepoint
48 h post exposure contrast media
Method of measurement
creatinine test
2
Description
Mortality
Timepoint
48 h post exposure contrast media
Method of measurement
Medical record
Intervention groups
1
Description
Intervention group: Group II was received Atorvastatin 80mg before coronary procedures (Atorvastatin 80 mg).
Category
Prevention
2
Description
Intervention group: Group III was administered N-acetylcysteine orally as a total dose of 1200 mg before and 600 mg after the coronary procedure (NAC 1800 mg).
Category
Prevention
3
Description
Intervention group: Group IV was prescribed 80 mg of Atorvastatin before and after the coronary procedure plus N-acetylcysteine as a sum of 1200 mg before and 600 mg after the coronary procedure (Atorvastatin 80 mg plus NAC 1800 mg).
Category
Prevention
4
Description
Control group: Group I was considered as control.They received neither Atorvastatin nor N-acetylcysteine before Coronary procedures.
Category
Prevention
Recruitment centers
1
Recruitment center
Name of recruitment center
Ali-ebn Abitaleb hospital
Full name of responsible person
Saeed Keshtkar
Street address
Ali-ebn Abitaleb hospital, Salamat Blvd., Khalij Fars high way
City
Zahedan
Province
Sistan-va-Balouchestan
Postal code
9816743111
Phone
+98 54 3329 5570
Email
s.keshtkar20@gmail.com
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Zahedan University of Medical Sciences
Full name of responsible person
Nour Mohammad Bakhshani
Street address
Zahedan University of Medical Sciences, Dr Hesabi square
City
zahedan
Province
Sistan-va-Balouchestan
Postal code
9816737789
Phone
+98 54 3329 5717
Email
parcomss97@gmail.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
No
Title of funding source
Research and technology department
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic
Person responsible for general inquiries
Contact
Name of organization / entity
Zahedan University of Medical Sciences
Full name of responsible person
Saeed Keshtkar
Position
general practitioner
Latest degree
Medical doctor
Other areas of specialty/work
Cardiology
Street address
Zahedan University of Medical Sciences, Dr Hesabi square, Zahedan
City
zahedan
Province
Sistan-va-Balouchestan
Postal code
9816737789
Phone
+98 54 3329 5717
Email
s.keshtkar20@gmail.com
Person responsible for scientific inquiries
Contact
Name of organization / entity
Zahedan University of Medical Sciences
Full name of responsible person
Saeed Keshtkar
Position
general practitioner
Latest degree
Medical doctor
Other areas of specialty/work
Cardiology
Street address
Zahedan University of Medical Sciences, Dr Hesabi square, Zahedan
City
zahedan
Province
Sistan-va-Balouchestan
Postal code
9816737789
Phone
+98 54 3329 5717
Email
s.keshtkar20@gmail.com
Person responsible for updating data
Contact
Name of organization / entity
Zahedan University of Medical Sciences
Full name of responsible person
Saeed Keshtkar
Position
general practitioner
Latest degree
Medical doctor
Other areas of specialty/work
Cardiology
Street address
Zahedan University of Medical Sciences, Dr Hesabi square, Zahedan
City
zahedan
Province
Sistan-va-Balouchestan
Postal code
9816737789
Phone
+98 54 3329 5717
Email
s.keshtkar20@gmail.com
Sharing plan
Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available